Vestikap, 16 mg capsules 30 pcs

Cerebral Circulatory Disorder, Meniere’s Disease, Dizziness

Indications

treatment of Meniere’s syndrome, characterized by dizziness (accompanied by nausea and vomiting), hearing loss and tinnitus;
symptomatic treatment of vestibular dizziness (vertigo).

Pharmacological effect

Pharmacotherapeutic group: Histamine preparation

Pharmacological action

An agonist of histamine H1 receptors and an antagonist of H3 receptors in the vestibular nuclei of the central nervous system. By relaxing the precapillary sphincters of the vessels of the inner ear, it improves blood circulation in the stria vascularis of the inner ear.

Dose-dependently reduces the generation of action potentials in neurons of the lateral and medial vestibular nuclei.

Accelerates the restoration of vestibular function after unilateral vestibular nephrectomy, accelerating and facilitating central vestibular compensation (due to antagonism with H3-histamine receptors).

Relieves symptoms of Meniere’s syndrome and vestibular vertigo. A stable therapeutic effect occurs after 14 days.

Pharmacokinetics

Suction and distribution

After taking the drug orally, betahistine is rapidly absorbed, binding to plasma proteins is less than 5%. Time to reach Cmax in plasma 1 hour

Metabolism and excretion

Metabolized to inactive metabolites: 2-pyridylacetic acid (main metabolite) and demethylbetagistine.

85-90% is excreted by the kidneys in the form of 2-pyridylacetic acid within 24 hours. Excretion of betahistine and demethylbetagistine by the kidneys is insignificant. Only a small part of betahistine and its metabolites is excreted through the intestines.

When taking the drug with food, the Cmax of betahistine in plasma is lower than when taken on an empty stomach. However, the total absorption of betahistine is the same in both cases, indicating that food intake only slows down the absorption of betahistine.

Special instructions

The therapeutic effect in some cases increases within several months from the start of treatment.

Impact on the ability to drive vehicles and machinery

No or minor impact.

Active ingredient

Betahistine

Composition

Active substance: betahistine

Excipients: lactose monohydrate (milk sugar), microcrystalline cellulose, potato starch, copovidone, sodium carboxymethyl starch, colloidal silicon dioxide, magnesium stearate.

Pregnancy

The use of the drug is contraindicated during pregnancy and lactation.

Contraindications

hypersensitivity to any of the components of the drug;
pregnancy;
lactation period;
pheochromocytoma;
children under 18 years of age;
lactose intolerance, lactase deficiency and glucose-galactose malabsorption syndrome.

With caution: peptic ulcer of the stomach or duodenum (including a history), bronchial asthma.

Side Effects

From the digestive system: nausea, vomiting, abdominal pain, bloating.

From the skin: angioedema, urticaria, itching, rash.

Allergic reactions: hypersensitivity, incl. anaphylactic reactions.

From the nervous system: headache.

Interaction

The interaction of betahistine with histamine H1 receptor blockers when used concomitantly may theoretically affect the effectiveness of one of these drugs.

Overdose

Symptoms: nausea, abdominal pain, drowsiness (when taken at a dose of up to 640 mg); seizures, cardiovascular complications (when taken at a dose of more than 640 mg or in combination with other drugs).

Treatment: symptomatic.

Storage conditions

The drug should be stored in a dry place, protected from light, out of reach of children, at a temperature not exceeding 25°C.

Shelf life

Shelf life – 3 years.

Manufacturer

Ozon, Russia